Phase III trial of Kadcyla shows benefits in Breast Cancer
Results from TH3RESA, a Phase III clinical trial of Kadcyla (ado trastuzumab emtansine), also known as T-DM1, from Genentech/Roche, show that it significantly improves the length of time before the disease worsens in women with advanced HER2 positive Breast Cancer whose disease has recurred or progressed despite previous treatments. Results showed that median progression-free survival increased by nearly three months from 3.3 months for the conventionally treated patients to 6.2 months for patients receiving Kadcyla. Among the Kadcyla patients, 31.3% showed a response to the drug, compared with 8.6% with conventional treatments.
An interim analysis of overall patient survival showed a similar trend, but it did not reach the level at which a statistically significant benefit for Kadcyla treatment could be confirmed. Generally, there were fewer serious adverse side-effects in the Kadcyla patients than in the control group. Data was presented by Professor Hans Wildiers at the 2013 European Cancer Congress.
Related news and insights
Genentech/Roche announced that the FDA has approved Susvimo (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant for the treatment of people with wet, or neovascular, age-related macular degeneration (AMD) who have previously responded to at least two anti-vascular endothelial growth factor (VEGF) injections.
Oncopeptides announced that the company has decided to withdraw Pepaxto (INN melphalan flufenamide) from the market in the US, following the phase III OCEAN study, which showed an overall survival in the ITT population with a HR of 1.104. The decision has been made after interactions and dialogue with the FDA. Pepaxto was granted accelerated approval on February 26th 2021.
Johnson & Johnson announced the FDA has issued Emergency Use Authorization (EUA) for a booster dose of the Johnson & Johnson COVID-19 vaccine for adults aged 18 and older at least two months following primary vaccination with single-shot Johnson & Johnson COVID-19 vaccine; and for eligible individuals who received a different authorized or approved COVID-19 vaccine.